| Literature DB >> 34905022 |
Neringa Jurkute1,2, Fabiana D'Esposito3,4, Anthony G Robson1,2, Robert D S Pitceathly5, Francesca Cordeiro3, F Lucy Raymond6,7, Anthony T Moore1,2,8, Michel Michaelides1,2, Patrick Yu-Wai-Man1,2,9,10, Andrew R Webster1,2, Gavin Arno1,2,11.
Abstract
Purpose: To report novel genotypes and expand the phenotype spectrum of SSBP1-disease and explore potential disease mechanism.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34905022 PMCID: PMC8684315 DOI: 10.1167/iovs.62.15.12
Source DB: PubMed Journal: Invest Ophthalmol Vis Sci ISSN: 0146-0404 Impact factor: 4.799
Figure 1.Pedigrees of families 1 through 5 and identified SSBP1 variants. An arrow indicates proband. Shaded symbols represent affected individuals. Different shading indicates dual pathology: SSBP1-disease (black) and other (grey). Asterisk (*) indicates additional pathogenic genotype identified in family 1 (GC17489). M, mutation; WT, wild type.
Figure 2.Variant location and conservation. (A) Schematic diagram of SSBP1 gene and SSBP1 protein. The identified variants are indicated on the top at the corresponding exons of the SSBP1 gene. Autosomal dominant variants are indicated on the top of the bar and autosomal recessive variants are indicated on the bottom of the bar at the corresponding positions of the SSBP1 protein. Novel variants indicated in red. (B) Multiple alignment of SSBP1 orthologues. All affected residues are strictly conserved in mammalian orthologues. Autosomal dominant variants are indicated in blue and autosomal recessive variants in red.
SSBP1 Variants Identified in the Current Study
| Family | HGVs | HGVp | Inheritance | gnomAD (MAF) | In Silico | ACMG (accessed May 2021) | Variant Reported | Total Number of Families Carrying Variant (Current Study and Reported) |
|---|---|---|---|---|---|---|---|---|
| Family_1 | c.151A>G | p.(Lys51Glu) | AD | – | Disease causing | Likely pathogenic | This study | 1 |
| GC17489 | (PM2, PP1, PP2, PP3) | |||||||
| Family_2 | c.113G>A | p.(Arg38Gln) | AD | – | Disease causing | Pathogenic | Jurkute et al. (2019) | 5 |
| GC17222 | (PS3, PM1, PM2, PP2, PP3) | Piro-Megy et al. (2020) | ||||||
| Family_3 | c.320G>A | p.(Arg107Gln) | AD | – | Disease causing | Pathogenic | Jurkute et al. (2019) | 7 |
| GC19412 | (PS3, PM1, PM2, PM6, PP2, PP3) | Del Dotto et al. (2020) Piro-Megy et al. (2020) Lee et al. (2021) | ||||||
| Family_4 GC19484 | c.380G>A | p.(Arg127Gln) | AR | 0.00003989 (10 al.) | Disease causing | VUS (PM2, PP2, PP3) | This study | 1 |
| c.394A>G | p.(Ile132Val) | 0.00001417 (4 al.) | Disease causing | Likely pathogenic | Del Dotto et al. (2020) | 2 | ||
| (PS3, PM2, PP2, PP3, PP5) | ||||||||
| Family_5 | c.335G>A | p.(Gly112Glu) | AD | – | Disease causing | Likely pathogenic | This study | 1 |
| (PM1, PM2, PP2, PP3) | ||||||||
Mutation nomenclature was assigned in accordance with GenBank Accession number NM_003143.
ACMG, American College of Medical Genetics; AD, autosomal dominant; al., allele; AR, autosomal recessive; MAF, minor allele frequency; VUS, variant of uncertain significance.
Figure 3.Multimodal imaging composite of affected individuals (left eye only). Optos wide-field fundus imaging (left) shows different degrees of optic atrophy in all affected except II:3 (father, family 1) and proband (family 5). Fundus color photographs demonstrates various degrees of retinal vessels attenuation, pigmentary changes and retinal atrophy in all affected except II:3 (family 1). Optos wide-field fundus autofluorescence images (middle) indicates areas of retinal atrophy with patches of decreased autofluorescence. SD-OCT macula imaging (right) of affected individuals shows various degree loss of inner and outer retina with very mild changes observed in asymptomatic individual (II:3, family 1). The overall retinal thickness is significantly reduced in individuals from family 2, family 3, family 4 and loss of retinal architecture in proband from family 5. Only SD-OCT imaging of proband from family 1 shows signs of the previously described foveopathy, that is, a focal loss of the outer retinal structures.
Figure 4.Electrophysiological recordings. International-standard pattern ERG (PERG), pattern and flash VEP (PVEP; FVEP) recordings from family 1 individual III:2 (at ages of 13 and 26 years) and her father II:3 (at ages of 46 and 52 years). Waveforms from right (RE) and left (LE) eyes are superimposed to demonstrate reproducibility. See text for details.
Figure 5.RGC layer thickness maps overlayed with macula grid (1.0, 2.22, and 3.45 mm diameters) on SD-OCT scans in II:3 (family 1) and control. RGC thickness heatmaps indicate RGC layer thinning in II:3 from family 1 (top left panel). For comparison, control RGC thickness heatmaps (top right) illustrates normal RGC layer thickness. Bottom panel show mean volume of RGC layer thicknesses in each of the nine subfields as measured using SD-OCT.
Phenotypic Features Identified in Patients
| Family | Individual | Sex | Age of Onset | Latest BCVA | Ocular Phenotype | Visual Electrophysiology (Age at Testing in Years) | Other Signs and Symptoms (Age at Presentation) |
|---|---|---|---|---|---|---|---|
| Family_1 GC17489 | Father (II:3) | M | Adolescence | RE 6/12 | Myopia (mild) | RGC/ON dysfunction (46) | – |
| LE 6/9 | Minimal worsening in LE over 6 years | ||||||
| Proband (III:2) | F | Early childhood (3) | RE HM LE HM | Optic atrophy Retinal dystrophy Foveopathy Attenuated retinal vessels | RGC/ON dysfunction (13) Marked worsening over 13 years | Migraine Postural orthostatic tachycardia syndrome (23 years) Fatigue (18–19 years) Anemia Parasthesia in hands and feet Anxiety Vertigo Asthma | |
| Full-sibling (III:3) | M | Early childhood (3) | RE 3/60 LE 3/60 | Optic atrophy Retinal dystrophy | Rod–cone dysfunction | CRX-associated retinal dystrophy Mild learning disability Short-term memory problems Delayed speech Parasthesia in hands and feet Postural tremor Short term memory problem | |
| Family_2 GC17222 | Proband | F | Adolescence (18) | RE 3/60 LE 3/60 | Optic atrophy Retinal dystrophy Attenuated retinal vessels Myopia | Rod–cone dysfunction Severe macular involvement | – |
| Family_3 GC19412 | Proband | M | Early childhood (3) | RE 1/60 LE 1/60 | Optic atrophy Retinal dystrophy Attenuated retinal vessels Myopia (moderate) | ON dysfunction Rod-cone dysfunction | Scoliosis (5 years) Episode of febrile convulsion (3 years) Developmental delay |
| Family_4 GC19484 | Proband | M | Adolescence (15) | RE 6/60 LE 6/48 | Optic atrophy Retinal dystrophy Attenuated retinal vessels Early cataracts Myopia (mild) | ND | Hearing loss (2.5 years) Poor coordination, which normalized later (15 years) Coeliac disease (1 year) Speech and language developmental delay |
| Family_5 | Proband | M | Adulthood (59) | RE 6/9.5 | Retinal dystrophy | ND | – |
| LE 6/7.5 | |||||||
Dual retinal dystrophy in affected individual.
HM, hand motions; LE, left eye; ND, no data; ON, optic nerve; RE, right eye.
Figure 6.Three-dimensional modelling of SSBP1 using protein databank crystal structures: 3ULL and 6RUP. The tetramer of SSBP1 (top left) was modelled using 3ULL template. Affected residues are indicated in red within molecule A. The bottom left panel is a schematic representation of how the heavy strand of mtDNA wraps around the SSBP1 tetramer based on dual resonance frequency-enhanced electrostatic force microscopy (DREEM) imaging studies by Kaur et al. The top right panel shows residues (red) located within the electropositive patches of SSBP1 as described by Yang et al. Bottom right panels are zoomed in on the residues that showed an alteration of hydrogen bonds in wildtype (WT) and mutant (M). Mutant modelling was performed using the 6RUP dimer (for Arg38 and Arg107) and 3ULL tetramer (For Arg107). Identified hydrogen bonds (dashed yellow lines) are indicated in both, WT and M molecules, with labelling in WT only. Mutant residues are shown in red. Binding partners are highlighted (black, within MolA; red, MolB or MolD).
A summary of Residues Hydrogen Bonds in Wild Type and Mutant (Molecule A) and Their Possible Effect on Protein Function and Structure
| Disease | Residue | Patch | MolA | Mutant | Amino Acid Charge Change | Possible Effect on Function and/or Structure of Protein |
| AD | Arg38 | Patch B | MolA Arg38–MolB Glu27 MolA Arg38–MolA Gly105 MolA Arg38–MolA Ala60 | HB with Gly105 is lost | From positive to not charged | WT: Direct contact with ssDNA; higher structure formation M: Reduced affinity to bind ssDNA; affected assembly |
| Lys51 | Patch A | MolA Lys51–MolA Val48 | HB remain intact | From positive to negative | WT: Direct contact with ssDNA M: Reduced affinity to bind ssDNA | |
| Arg107 | Patch B | MolA Arg107–MolB Arg28 MolA Arg107–MolD Ile138 | HB with Leu140 and Ile138 is lost | From positive to not charged | WT: Direct contact with ssDNA; higher structure formation M: Reduced affinity to bind ssDNA; affected assembly | |
| Gly112 | Adjacent to patch C | MolA Gly112–MolA Val33 | HB remains intact | No change | WT: Unknown M: Unknown | |
| AR | Arg127 | Patch A | MolA Arg127–MolA Tyr119 | HB remains intact | From positive to not charged | WT: Direct contact with ssDNA; higher structure formation M: Reduced affinity to bind ssDNA; affected assembly |
| Ile132 | MolA Ile132–MolA Ser88 MolA Ile132–MolA Arg86 | HB remain intact | No change | Previous functional assays showed that mutant leads to lower thermostability of the tetramer. | ||
Electropositive patch as identified by Yang at al. Patch A consists of Arg46, 46–52, Trp84, Arg86, 119–126 and Arg127 residues; patch B of Arg28, Arg38, Lys104, Arg107 residues; patch C of Trp65, Arg66, Lys81, Phe90, Arg91 and Lys113 residues; and patch D of Lys122 and Arg126 residues.
HB binding Arg107 with an Ile138 in opposing dimer is observed in tetramer using 3ULL template.
AD, autosomal dominant; AR, autosomal recessive; HB, hydrogen bond; M, mutant; MolA, molecule A; MolB, molecule B; MolC, molecule C; MolD, molecule D; ssDNA, single stranded DNA; WT, wild type.
Figure 7.Three-dimensional modelling of SSBP1 using protein databank crystal structure: 6RUP. Each panel demonstrates zoomed residues in wildtype (WT) and mutant (M) for the residues, which did not show altered hydrogen bonds in mutant. Identified hydrogen bonds (dashed yellow lines) are indicated in both, WT and M molecule, with labelling in WT only.
Residues Located Within the Electropositive Patches of SSBP1
| Patch | Residue Yang et al. | Residue NM_003143.3 | Variant in the Patch/Adjacent to the Patch |
|---|---|---|---|
| Arg30 | Arg46 | ||
| 30–37 | 46–52 | ||
| A | Trp68 | Trp84 | p.(Lys51Glu) |
| Arg70 | Arg86 | p.(Arg127Gln) | |
| 119–126 | 119–126 | ||
| Arg111 | Arg127 | ||
| Arg12 | Arg28 | ||
| B | Arg22 | Arg38 | p.(Arg38Gln) |
| Lys88 | Lys104 | p.(Arg107Gln) | |
| Arg91 | Arg107 | ||
| Trp49 | Trp65 | ||
| Arg50 | Arg66 | ||
| C | Lys65 Phe74 Arg75 Lys97 | Lys81 Phe90 Arg91 Lys113 | p.(Gly112Glu) |
| D | Lys106 | Lys122 | p.(Arg127Gln) |
| Arg110 | Arg126 | ||
The sequence indicated by Yang et al. was reviewed and residues were assigned to up to date annotation (NM_003143.3).